(Q38161572)

30 August 2017

title

Assessment of nonsteroidal anti-inflammatory drug-induced cardiotoxicity (English)

1 reference

30 August 2017

Bhulan Kumar Singh

1

1 reference

30 August 2017

Syed Ehtaishamul Haque

series ordinal

2

1 reference

30 August 2017

Krishna Kolappa Pillai

series ordinal

3

1 reference

30 August 2017

language of work or name

English

0 references

publication date

12 November 2013

1 reference

Expert Opinion on Drug Metabolism & Toxicology

30 August 2017

published in

1 reference

30 August 2017

volume

10

1 reference

30 August 2017

issue

2

1 reference

30 August 2017

page(s)

143-156

1 reference

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

NSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Inducible COX-2 dominates over COX-1 in prostacyclin biosynthesis: mechanisms of COX-2 inhibitor risk to heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Nonsteroidal anti-inflammatory drugs and cardiovascular risk: is prostacyclin inhibition the key event?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

COX-2-derived prostacyclin modulates vascular remodeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Cyclooxygenase inhibition and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Diclofenac sodium, a nonselective nonsteroidal anti-inflammatory drug aggravates doxorubicin-induced cardiomyopathy in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Cyclooxygenase-2 inhibition improves vascular endothelial dysfunction in a rat model of endotoxic shock: role of inducible nitric-oxide synthase and oxidative stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

New insights into the mechanism of action of acetaminophen: Its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Cardiovascular effects of cannabinoids in conscious spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Acetaminophen increases blood pressure in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Nonsteroidal antiinflammatory drugs, acetaminophen, and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Effect of naproxen and acetaminophen on blood pressure lowering by ramipril, valsartan and aliskiren in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Coxibs and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal anti-inflammatory drugs: study in mitochondria, submitochondrial particles, cells, and whole heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Nephrotic syndrome and acute tubular necrosis due to meloxicam use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Efficacy, safety, and effects on blood pressure of naproxcinod 750 mg twice daily compared with placebo and naproxen 500 mg twice daily in patients with osteoarthritis of the hip: a randomized, double-blind, parallel-group, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Celecoxib for the prevention of sporadic colorectal adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Celecoxib for the prevention of colorectal adenomatous polyps

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Naproxen aggravates doxorubicin-induced cardiomyopathy in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Effect of evening primrose oil and ω-3 polyunsaturated fatty acids on the cardiovascular risk of celecoxib in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Cyclooxygenase 2-selective and nonselective nonsteroidal anti-inflammatory drugs induce oxidative stress by up-regulating vascular NADPH oxidases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Diclofenac and acute myocardial infarction in patients with no major risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Cyclooxygenase-2 inhibitors and coronary occlusion--exploring dose-response relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Blood pressure destabilization on nonsteroidal antiinflammatory agents: acetaminophen exposed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Frequency of analgesic use and risk of hypertension in younger women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Non-narcotic analgesic dose and risk of incident hypertension in US women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Frequency of analgesic use and risk of hypertension among men

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Acetaminophen use and change in blood pressure in a hypertensive population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: A class effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.856881

10.1517/17425255.2014.856881

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference